EUVIMEDEUVIMED entdecken
Crossref

Distinct patterns of pituitary dysfunction in combination immunotherapy with nivolumab and ipilimumab

Aya Sakurai, Takuro Hakata iD, Ichiro Yamauchi iD, Sadahito Kimura, Daisuke Kosugi, Taku Sugawa, Haruka Fujita, Kentaro Okamoto, Yohei Ueda iD, Daisuke Taura iD, Daisuke Yabe iD

European Journal of Endocrinology · 2026

DOI: 10.1093/ejendo/lvag031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Endocrinology, 2026. Verfasst von Aya Sakurai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507…. Hauptthemen laut MEDLINE: Ipilimumab, Nivolumab, Immunotherapy, Hypopituitarism. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Japan Society, KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but are associated with immune-related adverse events (irAEs), including pituitary dysfunction. Combination immunotherapy with PD-1 and CTLA-4 inhibitors increases the risk of pituitary irAEs compared to PD-1 monotherapy; however, their detailed characteristics remain unclear. We aimed to clarify the clinical features of pituitary irAEs induced by combination immunotherapy.

Design

In this retrospective cohort study, we compared patients treated with combination therapy of nivolumab and ipilimumab (Nivo/Ipi) to those receiving nivolumab monotherapy (Nivo). We analyzed clinical data including presenting symptoms, laboratory findings, pituitary MRI results, and coexisting irAEs.

Results

Pituitary irAEs were more frequent in the Nivo/Ipi group (17.4%) than in the Nivo group (2.7%) and developed earlier (median onset: 63 vs 153 days, respectively). All 15 patients in the Nivo group presented with isolated ACTH deficiency (IAD), whereas the Nivo/Ipi group included 8 cases of IAD and 8 cases of combined pituitary hormone deficiency (CPHD). In the Nivo/Ipi group, CPHD occurred significantly earlier than IAD (median onset: 40 vs 84 days) and was associated with a higher incidence of headache and pituitary swelling on MRI. Furthermore, 75% of patients with CPHD also experienced non-endocrine irAEs. Two CPHD patients experienced worsening of symptoms and pituitary dysfunction following re-administration of Nivo/Ipi.

Conclusion

Pituitary irAEs are more frequent and develop earlier in patients receiving Nivo/Ipi. CPHD and IAD, induced by this combination immunotherapy, exhibit distinct clinical courses. Recognizing these differences is crucial for the optimal management of pituitary irAEs during combination immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IpilimumabNivolumabImmunotherapyHypopituitarismImmune Checkpoint InhibitorsPituitary DiseasesAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleRetrospective StudiesMiddle AgedAgedAdrenocorticotropic HormoneAdultEndocrine System DiseasesHypoglycemiaGenetic Diseases, Inborn

Stichwörter der Autor:innen

combined pituitary hormone deficiencyimmune checkpoint inhibitorimmune-related adverse eventisolated ACTH deficiencypituitary dysfunction

Substanzen

IpilimumabNivolumabAdrenocorticotropic HormoneImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.

ORCID-Profile: Takuro Hakata, Ichiro Yamauchi, Yohei Ueda, Daisuke Taura, Daisuke Yabe

Förderung

  • Japan Society
  • KAKENHI

Zitieren

APA

Sakurai, A., Hakata, T., Yamauchi, I., Kimura, S., Kosugi, D., Sugawa, T., Fujita, H., Okamoto, K., Ueda, Y., Taura, D., & Yabe, D. (2026). Distinct patterns of pituitary dysfunction in combination immunotherapy with nivolumab and ipilimumab. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvag031

Vancouver

Sakurai A, Hakata T, Yamauchi I, Kimura S, Kosugi D, Sugawa T, et al. Distinct patterns of pituitary dysfunction in combination immunotherapy with nivolumab and ipilimumab. European Journal of Endocrinology. 2026. doi:10.1093/ejendo/lvag031

BibTeX
@article{Sakurai2026,
  author = {Sakurai, Aya and Hakata, Takuro and Yamauchi, Ichiro and Kimura, Sadahito and Kosugi, Daisuke and Sugawa, Taku and Fujita, Haruka and Okamoto, Kentaro and Ueda, Yohei and Taura, Daisuke and Yabe, Daisuke},
  title = {Distinct patterns of pituitary dysfunction in combination immunotherapy with nivolumab and ipilimumab},
  journal = {European Journal of Endocrinology},
  year = {2026},
  doi = {10.1093/ejendo/lvag031}
}
Kostenlos starten →